New data shows that the use of the FreeStyle® Free Abbott System significantly reduces HbA1c levels in people with type 2 diabetes

SAN FRANCISCO, June 8, 2019 / PRNewswire / – Today, Abbott (NYSE: ABT) has announced new data showing that its FreeStyle Libre system, the company's groundbreaking continuous glucose monitoring (CGM) technology, is dramatically reducing the levels of energy. Hemoglobin A1c (HbA1c) for people with type 2 diabetes on intensive insulin therapy.² The results were analyzed from real-world retrospective data in three Europe  presented at the 79th Scientific Session of the American Diabetes Association (ADA) to the American Diabetes Association (Abstract 99-LB) at San Francisco.

The objective of the combined analysis of three individual studies was to determine the impact of using the FreeStyle Libre system on glycemic control in people under intensive insulin therapy with type 2 diabetes, the most common form of diabetes. when the body is unable to produce enough. insulin to maintain normal blood sugar. The researchers evaluated the anonymized records of 363 people on la France, Germany and L & # 39; Austria, evaluating their hbA1c levels over a period of three to six months in people aged around 63 who use insulin several times a day for more than eight years on average.

Results – the first time researchers have evaluated actual data specifically from people with type 2 diabetes using the FreeStyle Free system³ – have shown lower HbA1c levels with the use of Abbott technology after at least three months of use. The nearly 1% (-0.9% or -9.7 mmol / mol) decrease in HbA1c represents a significant reduction in blood glucose compared to the 7% target recommended for A1c A1c of ADA in adults with diabetes (excluding pregnant women).⁴

Other notable discoveries have shown:

• The mean HbA1c level was 8.9% (73.3 mmol / mol) before FreeStyle Free System use and 8.0% (63.6 mmol / mol) after the use of the FreeStyle Free System and 8.0% (63.6 mmol / mol). use of technology.
• No difference was detected based on age group, sex, body mass index or duration of insulin use, which indicates that the results apply to the large population of people with type 2 diabetes and not just a particular subset.

"These concrete results show how Abbott's FreeStyle Libre system can fundamentally change the way people manage their diabetes, especially for people with type 2 diabetes," said Helene Hanaire, MD, University Hospital Center for Alzheimer's. Toulouse in Toulouse, Franceand one of the main authors of the study. "By using real-time results, trends, and patterns of technology, people with diabetes are becoming more involved in making better decisions to control their blood glucose levels and improve their own health."

Real-world data and clinical research highlight FreeStyle Libre's role in potential change in standard of care

A1c hemoglobin levels, which reflect a person's average blood glucose over a three-month period, serve as a baseline for indicating the risk of developing long-term complications of diabetes. For people who manage diabetes, the goal of achieving normal levels of A1c is one of the critical success measures because it correlates with long-term health outcomes. These real-world data, combined with a recently published study on independent, randomized controlled trials Diabetic treatments, further confirms that the use of FreeStyle Libre significantly reduces hbA1c levels and improves glycemic control in people with type 2 diabetes.⁵

In addition, more and more evidence is showing access to remaining time (TIR) ​​and reports such as Ambulatory Glucose Profile (AGP), which provides a more simplified and clear overview of rates and trends in over time, can be valuable tools for improving glycemic control and improving blood glucose levels. the standard of care in addition to the HbA1c to better manage diabetes.

"Doctors tell us that FreeStyle Libre is changing the course of care for people with diabetes, and the combination of these real data and clinical research is further evidence that our technology can dramatically reduce the rate of diabetes." HbA1c in people with type 2 diabetes. " Mahmood Kazemi, M.D., Division Vice President, Global Medical and Scientific Affairs, Diabetes Care, Abbott. "This adds to the growing evidence of more than half a million users in real-life environments showing that the use of FreeStyle Free is associated with improved blood glucose control and better results in patients. With more than 425 million people living with diabetes worldwide, Abbott's technology offers tremendous opportunities to change more lives and the future of people with diabetes. "

Abbott's FreeStyle Libre system is now used by more than 1.5 million people with diabetes in 46 countries.⁶ Abbott has obtained a partial or full refund of the FreeStyle Libre system in 33 countries, including la France, Ireland, Japan, the United Kingdomand the 14-day FreeStyle Free US System is also available to Medicare patients in the United States based on eligibility.⁷ For more information, please visit www.freestylelibre.us.

For the US version of FreeStyle Libre, information and important safety information can be found below.

IMPORTANT INFORMATION AND INFORMATION ON SAFETY
The FreeStyle Free 14-day Free Blood Glucose Monitoring System is a continuous blood glucose monitoring (CGM) device designed to replace blood glucose, detect trends and determine trends, to detect episodes of hyperglycemia and of hypoglycemia, thus facilitating acute and long-term therapeutic adjustments. in people (aged 18 and over) with diabetes. The system is intended to be used by a single patient and requires a prescription.

Cons-indications: Remove the sensor before MRI, CT, x-ray, or diathermy treatment.

WARNINGS / LIMITATIONS: Do not ignore symptoms that may be due to low or high blood sugar, unconsciousness of hypoglycaemia or dehydration. Check the meter's glucose readings with a meter when the blood glucose check symbol appears, when the symptoms do not match those in the system, or if you think the measurements are inaccurate. The FreeStyle Free 14-day system has no alarms unless the sensor is scanned, and the system contains small parts that can be dangerous if swallowed. FreeStyle Free 14 days is not approved for pregnant women, dialysis patients or critically ill people. The position of the sensor is not approved for sites other than the back of the arm and standard precautions for the transmission of bloodborne pathogens must be taken. The integrated glucometer should not be used for dehydrated, hypotensive, shock, hyperglycaemic-hyperosmolar, with or without ketosis, neonates, critically ill patients, or for the diagnosis or screening of diabetes. Review all product information before use, contact Abbott toll free (855-632-8658) or visit www.freestylelibre.us for detailed information on usage and safety information.

About Abbott
Abbott is a global health leader that helps people live better at every stage of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading companies and products in the areas of diagnostics, medical devices, nutrition and branded generics. Our 103,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott, and on Twitter @AbbottNews and @AbbottGlobal.

SOURCE Abbott

Related Links

http://www.abbott.com